Home » Newsletters » BioWorld Science

BioWorld Science

April 5, 2012

View Archived Issues

Dalcetrapib continues to show positive effects on HDL cholesterol

Characterization of new ApoA-I formulation presented at different meetings

Aeterna Zentaris presents promising compound for cancer treatment

Astellas Pharma discloses new phosphodiesterase 9A inhibitors

New EthR inhibitor enhances antimycobacterial activity of ethionamide

Discovery and entry of ABT-199 into clinic reported at AACR meeting

University of Pittsburgh synthesizes new p53/Mdm2 antagonists

Novel microRNA-based tests classify tumor types with high accuracy

LabCorp licenses diagnostic technology for Alzheimer's disease

FDA extends review of Lymphoseek

GTx replies to FDA's clinical hold letter regarding Capesaris

Fresenius Medical Care gains marketing rights to TRK-820

Genzyme submits mipomersen NDA in U.S.

BLA submission completed for metreleptin

New recombinant therapy enters phase I trial in coronary artery disease

Xencor receives milestone payment from Boehringer Ingelheim

Hanmi Pharmaceutical's HM-47000 selected as a government project

Preclinical development of antibiotic completed

Sclerostin-directed antibody advances to phase III for osteoporosis

Shin Nippon Biomedical reports phase I data on intranasal zolmitriptan

New metabotropic glutamate mGlu5 receptor modulators designed

Novel BTK inhibitors reported

Takeda presents novel cognition-enhancing products

Trillium provides update on lead cancer program

FDA grants priority review to Zaltrap BLA

Mercury Pharma combination therapy approved in Scotland

Newron and Zambon provide update on safinamide

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.